Latest Insider Transactions at Exelixis, Inc. (EXEL)
This section provides a real-time view of insider transactions for Exelixis, Inc. (EXEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXELIXIS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXELIXIS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2025
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
7,535
-2.06%
|
$324,005
$43.09 P/Share
|
|
Jun 02
2025
|
Sue Gail Eckhardt Director |
SELL
Open market or private sale
|
Direct |
18,838
-23.42%
|
$810,034
$43.21 P/Share
|
|
May 29
2025
|
Bob Oliver Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+18.47%
|
-
|
|
May 29
2025
|
Mary C Beckerle Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+19.61%
|
-
|
|
May 29
2025
|
Julie Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+32.27%
|
-
|
|
May 29
2025
|
Sue Gail Eckhardt Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+19.61%
|
-
|
|
May 29
2025
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+0.76%
|
-
|
|
May 29
2025
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+8.87%
|
-
|
|
May 29
2025
|
Jack L Wyszomierski Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+2.61%
|
-
|
|
May 29
2025
|
George Poste Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+5.2%
|
-
|
|
May 29
2025
|
Tomas J. Heyman Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+18.84%
|
-
|
|
May 21
2025
|
Tomas J. Heyman Director |
SELL
Open market or private sale
|
Direct |
4,544
-12.28%
|
$199,936
$44.29 P/Share
|
|
May 20
2025
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
34,387
-7.7%
|
$1,513,028
$44.06 P/Share
|
|
May 16
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
72,776
-13.52%
|
$3,274,920
$45.47 P/Share
|
|
May 16
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+6.92%
|
$840,000
$21.75 P/Share
|
|
May 16
2025
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
87,871
+4.53%
|
-
|
|
May 16
2025
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
87,871
-5.47%
|
-
|
|
May 16
2025
|
Christopher J. Senner EVP and CFO |
SELL
Open market or private sale
|
Direct |
100,000
-9.36%
|
$4,600,000
$46.0 P/Share
|
|
May 16
2025
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+8.56%
|
$1,800,000
$18.8 P/Share
|
|
May 16
2025
|
George Poste Director |
SELL
Open market or private sale
|
Direct |
20,634
-10.88%
|
$928,530
$45.99 P/Share
|
|
May 16
2025
|
George Poste Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,634
+9.81%
|
$392,046
$19.77 P/Share
|
|
May 15
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,303
-1.64%
|
$365,332
$44.65 P/Share
|
|
May 15
2025
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
126,383
-11.43%
|
$5,940,001
$47.5 P/Share
|
|
May 15
2025
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
116,383
+17.13%
|
$2,094,894
$18.8 P/Share
|
|
May 15
2025
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
34,705
-7.07%
|
$1,527,020
$44.65 P/Share
|
|
May 15
2025
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-3.48%
|
$1,150,000
$46.18 P/Share
|
|
May 15
2025
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
34,035
-4.52%
|
$1,497,540
$44.65 P/Share
|
|
May 15
2025
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
104,769
-6.12%
|
$4,609,836
$44.65 P/Share
|
|
May 15
2025
|
Stelios Papadopoulos Director |
SELL
Open market or private sale
|
Direct |
36,508
-1.41%
|
$1,606,352
$44.35 P/Share
|
|
May 15
2025
|
Stelios Papadopoulos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,508
+1.39%
|
$730,160
$20.14 P/Share
|
|
May 15
2025
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
41,422
-4.1%
|
$1,822,568
$44.65 P/Share
|
|
May 15
2025
|
Dana Aftab CSO/EVP Disc & Trans Research |
SELL
Payment of exercise price or tax liability
|
Direct |
30,693
-4.43%
|
$1,350,492
$44.65 P/Share
|
|
May 14
2025
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
10,000
-2.0%
|
$420,000
$42.68 P/Share
|
|
May 14
2025
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
220,494
-11.42%
|
$9,701,736
$44.65 P/Share
|
|
May 14
2025
|
Michael Morrissey President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
308,365
+13.77%
|
$5,550,570
$18.8 P/Share
|
|
Mar 31
2025
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
170,009
+14.42%
|
-
|
|
Mar 31
2025
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
159,383
+24.16%
|
-
|
|
Mar 31
2025
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
154,070
+17.01%
|
-
|
|
Mar 31
2025
|
Dana Aftab CSO/EVP Disc & Trans Research |
BUY
Grant, award, or other acquisition
|
Direct |
132,819
+16.07%
|
-
|
|
Mar 31
2025
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
589,719
+26.65%
|
-
|
|
Mar 31
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
159,383
+23.94%
|
-
|
|
Mar 03
2025
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
10,000
-2.85%
|
$380,000
$38.8 P/Share
|
|
Feb 28
2025
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
8,768
-2.4%
|
$324,416
$37.8 P/Share
|
|
Feb 28
2025
|
Jack L Wyszomierski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,874
+4.16%
|
$317,480
$20.5 P/Share
|
|
Feb 28
2025
|
Julie Smith Director |
SELL
Open market or private sale
|
Direct |
19,294
-64.16%
|
$713,878
$37.62 P/Share
|
|
Feb 28
2025
|
Julie Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,294
+39.08%
|
$366,586
$19.77 P/Share
|
|
Feb 27
2025
|
Julie Smith Director |
SELL
Open market or private sale
|
Direct |
54,514
-83.49%
|
$2,071,532
$38.13 P/Share
|
|
Feb 27
2025
|
Julie Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
54,514
+34.48%
|
$1,090,280
$20.14 P/Share
|
|
Feb 26
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
52,192
+13.07%
|
-
|
|
Feb 26
2025
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
52,192
+8.03%
|
-
|